A dispute regarding government-imposed price caps on chemotherapy drugs has resulted in a critical shortage at state-run hospitals across the country. Despite the lack of availability in public facilities, these essential medications remain accessible elsewhere, but at significantly inflated prices. This situation creates a disparity in healthcare access, potentially hindering cancer patients’ treatment. The core of the problem lies in a disagreement between pharmaceutical suppliers and the government over fair pricing. Hospitals are unable to procure the drugs under the mandated price limits, while private markets are unaffected by these regulations. Consequently, patients relying on public healthcare are facing considerable challenges in continuing their chemotherapy regimens. Authorities are currently attempting to resolve the pricing conflict to restore drug supplies to state hospitals and ensure equitable care.